ClinicalTrials.gg
RecruitingNCT07371624Updated Aug 13, 2026

A Study of B2065 in Patients With Acute Ischemic Stroke

A Phase 1/2 interventional study of B2065 and Placebo in Acute Ischemic Stroke, sponsored by Tasly Pharmaceutical Group Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Tasly Pharmaceutical Group Co., Ltd (part of China Resources Pharmaceutical Group Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 753 studies in Ischemic Stroke with a site in China — 380 open to participants now, 399 under way, 78 of them phase 3. Ischemic Stroke · China.

Planned enrollment
500th of 565
54 · median 270
Started
2025
with 106 others
Phase 1/2
14 of 753
7 open now
Primary completion
2027-12
later than 255 of 398 live
Registered
642nd of 753
by date

Among the 753 studies in Ischemic Stroke with a site in China, this one is the 500th largest by planned enrollment of the 565 interventional ones that give a count, is one of 107 that started in 2025, is one of 14 in phase 1/2, reaches primary completion later than 255 of the 398 other live ones, and was the 642nd registered.

Ischemic Stroke

2,625 studies on the registry are indexed under Ischemic Stroke; 982 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

380 of the 753 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

375 more — sign in →

All 380 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 402 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 753 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety of B2065, an allogeneic adipose-derived mesenchymal stromal cell (AD-MSC) injection. It will also assess whether B2065 works to treat acute ischemic stroke. The main questions it aims to answer are:

At what dose range is the drug safe for participants?

Which dose shows preliminary efficacy?

Researchers will compare B2065 to a placebo (a look-alike substance that contains no drug) to see if B2065 works to treat acute ischemic stroke.

Participants will:

Receive a single dose of B2065 during hospitalization

Visit the hospital as scheduled for safety and efficacy assessments

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 75 years (inclusive of the boundary values), with no restriction on sex.
  2. Patients with ischemic stroke confirmed by imaging examinations (CT/MRI).
  3. Time from onset of stroke symptoms to administration of the product ≤36 hours; for wake-up stroke, the time of onset is defined as the last-known-well time (the last time the patient was observed to be normal).
  4. NIHSS score at screening is 8 to 20.
  5. The patient or legally authorized representative is willing to participate in this trial and agrees to sign the form.

Exclusion criteria

Exclusion Criteria

  1. Patients who have received intravenous thrombolysis and/or mechanical thrombectomy prior to dosing.
  2. Modified Rankin Scale (mRS) score ≥2 before stroke onset.
  3. Patients who currently have intracranial hemorrhagic diseases (e.g., intracerebral hemorrhage, epidural hematoma, subarachnoid hemorrhage, etc.), or who have brain tumors, cerebrovascular malformations, multiple sclerosis, a history of severe traumatic brain injury, encephalitis, or other conditions causing stroke-like symptoms.
  4. Patients who are unable to undergo CT and/or MRI examinations.
  5. Patients with decreased level of consciousness (NIHSS item 1a score ≥2).
  6. Patients who may have major neurologic or psychiatric disorders that seriously interfere with the participant's compliance with trial assessments.
  7. Body temperature >38°C prior to dosing, and the investigator assesses that there is a risk of infection.
  8. Patients with uncontrollable active infection; or patients who have received systemic anti-infective therapy within 7 days prior to dosing and, in the investigator's judgment, may be likely to convert to uncontrollable active infection in the short term.
  9. Patients with current or prior severe diseases of other organ systems, including but not limited to:

    1. Patients with severe heart failure ( Class III or IV) and/or severe respiratory failure;
    2. Patients with renal disease with estimated (eGFR) \<30 mL/min/1.73 m²;
    3. Advanced liver disease, such as hepatitis or liver cirrhosis;
    4. Patients positive for surface antigen (HBsAg) and/or hepatitis B e antigen (HBeAg); patients positive for hepatitis B e antibody (HBeAb) and/or hepatitis B core antibody (HBcAb) with quantitative HBV-DNA above the ; patients with any of the following test results positive: virus antibody (HCV-Ab), Treponema pallidum antibody (TP-Ab), or antibody (HIV-Ab);
    5. Patients with hypertension not controlled after taking therapeutic medications, with systolic blood pressure ≥185 mmHg and/or diastolic blood pressure ≥110 mmHg;
    6. Blood glucose \<2.8 mmol/L (50 mg/dL) or >22.2 mmol/L (400 mg/dL).
  10. Screening laboratory tests meeting any of the following criteria:

    1. Serum (ALT) ≥3× upper limit of normal (ULN);
    2. Serum aspartate aminotransferase (AST) ≥3× ULN;
    3. Serum creatinine (Cr) ≥2× ULN;
    4. (ANC) \<1.5×10\^9/L;
    5. count (PLT) \<100×10\^9/L;
    6. (Hgb) \<90 g/L;
    7. (INR) >1.7 or activated partial thromboplastin time (APTT) >1.25× ULN.
  11. Patients with malignant tumors or other diseases with an expected survival of less than 2 years.
  12. Patients with other acquired or congenital immunodeficiency diseases, or those currently using .
  13. Patients who, upon screening inquiry, have alcohol dependence or a history of drug abuse.
  14. Pregnant or breastfeeding women; or those who plan to conceive, donate sperm, or donate oocytes during the trial and/or are unwilling to take effective measures.
  15. Patients who participated in any other clinical trial within 1 month prior to screening.
  16. Patients who are allergic to any component of the product.
  17. Patients deemed by the investigator to be unsuitable for participation in this trial.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    B2065

    Phase I dose escalation includes 5.0×10\^7 cells (1 bag), 1.5×10\^8 cells (3 bags), and 4.5×10\^8 cells (9 bags), formulated in 1% human serum albumin and sodium chloride injection. Phase IIa dose expansion will select 1-2 dose cohorts from Phase I. Participants will be randomized in a 2:1 ratio (B2065:placebo).

    Drug: B2065

  • Placebo comparator
    Placebo

    Placebo (1% human serum albumin in sodium chloride injection) administered by intravenous infusion, with matched volume and number of bags.

    Drug: Placebo

Interventions

  • DrugB2065

    Administered by intravenous infusion.

  • DrugPlacebo

    Administered by intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicities (DLTs) [Safety]

    Percentage of participants experiencing DLTs during the Phase 1 dose-escalation stage.

    Time frame: Within 28 days after dosing.

  2. Incidence of Infusion-Related Reactions [Safety]

    Percentage of participants experiencing infusion-related reactions, including hypersensitivity reactions and systemic complications.

    Time frame: Within 7 days, 14 days, and 28 days.

  3. All-Cause Mortality Rate [Safety]

    Proportion of participants who die from any cause during the study period.

    Time frame: Within 14 days,12 months, and 24 months.

  4. Incidence of abnormal imaging findings indicative of tumorigenicity [Safety]

    Percentage of participants with newly detected tumorous lesions as assessed by chest and abdominal CT scans.

    Time frame: Month 6 and month 24.

  5. Change from baseline in serum tumor marker levels [Safety]

    Evaluation of serum levels of tumor markers

    Time frame: Change from baseline at Month 6 and Month 24.

  6. Incidence and severity of Treatment-Emergent Adverse Events (TEAEs) [Safety]

    Percentage of participants experiencing one or more TEAEs, serious adverse events (SAEs), or adverse events leading to study discontinuation.

    Time frame: Day1 to month 24 post-dose.

Secondary outcomes

  1. Proportion of participants achieving a modified Rankin Scale (mRS) score of 0-2 [Efficacy]

    Percentage of participants achieving functional independence (mRS score 0-2). The mRS is a 7-level scale ranging from 0 (no symptoms) to 6 (death).

    Time frame: Day 28, day 90, month 6, and month 12.

  2. Proportion of participants achieving a modified Rankin Scale (mRS) score of 0-1 [Efficacy]

    Percentage of participants achieving a favorable clinical outcome (mRS score 0-1).

    Time frame: Day 28, day 90, month 6, and month 12.

  3. Proportion of participants with neurological improvement based on NIH Stroke Scale (NIHSS) [Efficacy]

    Percentage of participants with a decrease in NIHSS score of ≥4 points from baseline, or achieving an absolute NIHSS score ≤1.

    Time frame: 24 hours, day 3, day 7, day 14, and month 12.

  4. Change from baseline in NIH Stroke Scale (NIHSS) score [Efficacy]

    Quantitative assessment of neurological deficit changes from baseline. Scores range from 0 (no deficit) to 42 (severe deficit).

    Time frame: 24 hours, day 3, day 7, day 14, and month 12.

  5. Proportion of participants achieving a Barthel Index (BI) score of 95-100 [Efficacy]

    Percentage of participants with slight or no disability (BI score 95-100). Total score ranges from 0 (complete dependence) to 100 (independence).

    Time frame: Day 28, day 90, month 6, and month 12.

  6. Change from baseline in EQ-5D-5L Index Score [Quality of Life]

    Standardized measure of health status across 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression).

    Time frame: Day 28, day 90, month 6, and month 12.

Other outcomes

  1. Change from baseline in serum Immunoglobulin levels (IgG, IgM, IgA, IgE) [Exploratory]

    Evaluation of humoral immune function changes post-dose.

    Time frame: Change from baseline at Day 3, Day 28, and Day 90 post-dose.

  2. Change from baseline in Regulatory T cells (Treg) percentage [Exploratory]

    Assessment of immune regulation response.

    Time frame: Change from baseline at Day 3, Day 28, and Day 90 post-dose.

  3. Change from baseline in serum Tumor Necrosis Factor-alpha (TNF-α) concentration [Exploratory]

    Assessment of systemic inflammatory response post-dose.

    Time frame: Change from baseline at Day 3, Day 28, and Day 90 post-dose.

  4. Change from baseline in serum Nerve Growth Factor (NGF) concentration [Exploratory]

    Quantitative assessment of neurotrophic factor levels post-dose.

    Time frame: Pre-dose and Day 7, Day 28, Day 90, and Month 12 post-dose.

  5. Incidence of Anti-Drug Antibodies (ADA) positivity [Exploratory]

    Percentage of participants who test positive for treatment-emergent anti-drug antibodies (immunogenicity).

    Time frame: Pre-dose and Day 14, Day 28, Day 90, and Month 12 post-dose.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2027, 24 months after the start.

Of 27 phase 1/2 interventional studies under Ischemic Stroke, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2026
First posted
Jan 28, 2026
StartActual
Dec 31, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07371624
Responsible party
Sponsor
First posted
Jan 28, 2026
Start date
Dec 31, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 13, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion